Close
Aamir Ahmed and Chris Thrasivoulou awarded patent for ground-breaking drug repurposing therapy
27 January 2022
Drs Aamir Ahmed (KCL Prostate Cancer Research Centre) and Dr Christopher Thrasivoulou (UCL Cell and Developmental Biology) have been awarded a patent by the EPO for their ground-breaking drug repurposing therapy for epithelial cancers such as breast and prostate.
Drs Aamir Ahmed (Prostate Cancer Research Centre, KCL Division of Surgery) and Christopher Thrasivoulou (UCL Cell and Developmental Biology) have been awarded a patent by the EPO for their ground-breaking drug repurposing therapy for epithelial cancers such as breast and prostate (European Patent No. 3060204). These cancers cause hundreds of thousands of deaths worldwide and are a significant cost burden for the NHS. Evidence based drug repurposing, use of drugs that are indicated for diseases other than cancer, can offer both clinical and cost-effective therapy for devastating diseases such as cancer. Another key advantage of such therapies is limited and known side effects, unlike the severe side effects of current cancer therapies.
Links:
https://worldwide.espacenet.com/patent/search/family/049727160/publication/EP3060204A2?q=3060204
https://www.jbc.org/article/S0021-9258(19)54289-2/fulltext
Image: A convergent model for the canonical (Wnt/β-catenin) and non-canonical (Wnt/Ca2+) Wnt signaling, in mammalian cell lines. Thrasivoulou, Millar & Ahmed.